Announcements Trials
Browse Landscape

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 22Observational 4Expanded_access 2

Sponsor

Cancer Type

Myeloid 4

Conditions

Polycythemia Vera 4Primary Myelofibrosis 1Bone Marrow Neoplasms 1

Interventions

ruxolitinib 4Watchful Waiting 2Blood Specimen Collection 2Valganciclovir 1Therapeutics 1Surveys and Questionnaires 1Polymerase Chain Reaction 1Magnetic Resonance Imaging 1Hydroxyurea 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Fentanyl 1Drug Therapy 1Dapsone 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Polycythemia Vera × ruxolitinib × Clear all
NCT05548062 2025-09-03

Prospero

Novartis

Active not recruiting
242 enrolled
Myeloid

Polycythemia Vera

NCT05853445 2024-05-06

PAVE

Novartis

Completed
467 enrolled
Myeloid

Polycythemia Vera

NCT05566535 2022-10-04

QoL-PV-R

Multinational Center for Quality of Life Research, Russia

Unknown
32 enrolled
Myeloid

Polycythemia Vera

NCT05421104 2022-07-05

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

Novartis

Completed
1,576 enrolled
Myeloid

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡